Academic literature on the topic 'Cancer du sein – Génétique'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Cancer du sein – Génétique.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Journal articles on the topic "Cancer du sein – Génétique":
Viassolo, Valeria, Aurélie Ayme, and Pierre O. Chappuis. "Cancer du sein : risque génétique." Imagerie de la Femme 26, no. 2 (June 2016): 95–104. http://dx.doi.org/10.1016/j.femme.2016.04.009.
Probst-Hensch, Nicole M., and Alfredo Morabia. "Epidémiologie génétique et susceptibilité génétique au cancer du sein." Revue Médicale Suisse -2, no. 2378 (2002): 301–5. http://dx.doi.org/10.53738/revmed.2002.-2.2378.0301.
Cohen-Haguenauer, Odile. "Prédisposition héréditaire au cancer du sein (1)." médecine/sciences 35, no. 2 (February 2019): 138–51. http://dx.doi.org/10.1051/medsci/2019003.
M, J. M. "Coalition internationale en génétique du cancer du sein." Revue Francophone des Laboratoires 2017, no. 492 (May 2017): 11. http://dx.doi.org/10.1016/s1773-035x(17)30143-0.
De Pauw, Antoine, and Dominique Stoppa-Lyonnet. "Le risque familial et génétique de cancer du sein." Soins 58, no. 776 (June 2013): 30–32. http://dx.doi.org/10.1016/j.soin.2013.04.005.
Eisinger, F. "Risque génétique de cancer du sein et de l'ovaire." Chirurgie 123, no. 4 (September 1998): 399–404. http://dx.doi.org/10.1016/s0001-4001(98)80013-5.
D., Y. M. "Cancer du sein : bientôt un test de prédisposition génétique." Option/Bio 23, no. 476 (July 2012): 5. http://dx.doi.org/10.1016/s0992-5945(12)71347-8.
Martel-Billard, C., C. Cordier, C. Tomasetto, J. Jégu, and C. Mathelin. "Cancer du sein et trisomie 21 : une anomalie génétique qui protège contre le cancer du sein ?" Gynécologie Obstétrique & Fertilité 44, no. 4 (April 2016): 211–17. http://dx.doi.org/10.1016/j.gyobfe.2016.02.016.
Nau, Jean-Yves. "Génétique des cancers du sein nouvelles lumières." Revue Médicale Suisse 3, no. 114 (2007): 1483. http://dx.doi.org/10.53738/revmed.2007.3.114.1483.
Cassier, Maurice, and Jean-Paul Gaudillière. "Recherche, médecine et marché : la génétique du cancer du sein." Sciences sociales et santé 18, no. 4 (2000): 29–51. http://dx.doi.org/10.3406/sosan.2000.1504.
Dissertations / Theses on the topic "Cancer du sein – Génétique":
Bonadona, Valérie. "Le cancer du sein de survenue précoce : aspects cliniques, épidémiologiques et génétiques à partir d'une étude prospective dans le Rhône." Lyon 1, 2005. http://www.theses.fr/2005LYO10191.
Fabbro, Michel. "Apport de la biologie moléculaire à l'épidémiologie génétique du cancer du sein." Montpellier 1, 1991. http://www.theses.fr/1991MON11083.
Ducy, Mandy. "Caractérisation fonctionnelle de variations génétiques dans PALB2, un gène de susceptibilité au cancer du sein." Doctoral thesis, Université Laval, 2019. http://hdl.handle.net/20.500.11794/35287.
Hamdi, Yosr. "Evaluation of the association between common genetic variants and breast cancer risk." Doctoral thesis, Université Laval, 2017. http://hdl.handle.net/20.500.11794/28384.
Breast cancer is the most common malignancy in women. A set of environmental and genetic factors are involved in this complex disease. This project focused on the genetic components of breast cancer susceptibility and breast cancer risk modification in BRCA1 and BRCA2 mutation carriers. Currently, about half of the inherited susceptibility to breast cancer can be imputed to a combination of high-, intermediate-, and low-risk alleles. Thus, many as yet unknown susceptibility loci remain to be identified. Moreover, recent studies have provided evidence for the involvement of genetic risk factors that might considerably modify the risk of developing breast cancer in BRCA1 and BRCA2 mutation carriers. Furthermore, genome-wide association studies have shown that several genetic variants within non-coding gene regions are associated with breast cancer risk. In this project, we focused on regulatory gene variants and their association with breast cancer risk. The project was divided in two parts. In the first section, we evaluated the direct association between single-nucleotide polymorphisms associated with differential allelic expression and breast cancer risk in order to identify new loci of breast cancer susceptibility. In the second part, we evaluated the functional impact on gene expression of variants identified within the promoter regions of selected candidate genes and then, characterize the functional impact of these variants. In summary, the first part of this project has led to the identification of a new low-penetrance locus associated with breast cancer risk on the 4q21 locus (rs11099601; odds ratio=1.05, p= 6.4 x 10-6), and two new modifiers of breast cancer risk in BRCA1 mutations carriers (11q22.3 locus and the wild type allele of BRCA1). The second part of the project allowed us to describe new functional variants within the promoters of the selected breast cancer gene candidates. Other association studies in larger cohorts and further functional analysis will be required to confirm these results, which will allow their inclusion in breast cancer risk prediction tools and thus ensure a more accurate estimation of breast cancer risk.
Stieber, Daniel. "Analyse génétique de la sensibilité au cancer mammaire." Doctoral thesis, Universite Libre de Bruxelles, 2005. http://hdl.handle.net/2013/ULB-DIPOT:oai:dipot.ulb.ac.be:2013/211000.
Fleury-Ricordeau, Laurence. "Modifications épigénétiques dans le cancer du sein." Toulouse 3, 2008. http://thesesups.ups-tlse.fr/301/.
In breast cancer, approximately one third of tumors express neither the estrogen receptor (ERa) nor estrogen regulated genes such as the Progesterone Receptor gene (PR). Our study provides new insights into the mechanism allowing hormone-activated expression of ERa target genes silenced in ERa-negative mammary tumor cells. In cell lines derived from ERa-negative MDA-MB231 cells, stable expression of different levels of ERa from a transgene did not result in transcription of PR. A quantitative comparative analysis demonstrates that inhibiting DNA methyltransferases using 5-aza-2'-deoxycytidine or specific disruption of DNMT1 by small interfering RNAs and treatment with the histone-deacetylase inhibitor Trichostatin A enabled ERa-mediated hormone-dependent expression of endogenous PR. We show that demethylation of a CpG island located in the first exon of PR was a prerequisite for ERa binding to these regulatory sequences. Although not a general requirement, DNA demethylation is also necessary for derepression of a subset of ERa target genes involved in tumorigenesis. PR transcription did not subsist four days after removal of the DNA methyltransferase blocking agents, suggesting that hormone-induced expression of ERa target genes in ERa-negative tumor cells is transient. Our observations support a model where an epigenetic mark confers stable silencing by precluding ERa access to promoters
Sabatier-Montiel, Danièle. "Amplification et surexpression de certains gènes associés à la cancerogénèse mammaire : étude de 148 cas de cancer du sein traités au C.R.L.C. Val d'Aurelle de 1988 à 1991." Montpellier 1, 1993. http://www.theses.fr/1993MON11200.
Ennour-Idrissi, Kaoutar. "Associations entre la longueur des télomères et les facteurs pronostiques du cancer du sein." Master's thesis, Université Laval, 2016. http://hdl.handle.net/20.500.11794/27561.
Telomeres are highly specialized structures capping the ends of chromosomes that ensure genome integrity during replication. As telomere length is an indicator of cell aging, telomere shortening has been linked to aging-related diseases, especially cancer. Several studies suggest that lifestyle factors, which are modifiable factors and have been associated with breast cancer prognosis, have an impact on telomere length and that telomere length may be associated with breast cancer prognosis. The present project objective was to investigate the association of telomeres with traditional and potential breast cancer prognostic factors. First, a systematic review was conducted to evaluate the current state of knowledge concerning the value of telomere length as a prognostic factor. This systematic review identified important methodological differences that could account for the overall inconclusive results of previous studies and highlighted the potential value of telomere length as a breast cancer prognostic marker. A cross-sectional exploratory study was then performed to examine the association of peripheral white blood cells telomere length with traditional and potential prognostic factors among 162 breast cancer patients consecutively recruited at the « Centre des maladies du sein Deschênes-Fabia » in Quebec City. This study identified a positive association between specific domains of physical activity and telomere length in peripheral white blood cells. Even though an association of telomere length with traditional breast cancer prognostic factors was not identified, the value of telomere length as a breast cancer prognostic marker deserves to be explored through an unbiased longitudinal survival study.
Bencheikh, Meryem. "Pertes d'hétérozygotie dans les cancers du sein : incidence et corrélations avec d'autres altérations génomiques." Montpellier 2, 1992. http://www.theses.fr/1992MON20065.
Plourde, Marie. "Identification et caractérisation des variants de séquences des gènes HSD17B1, HSD17B2, HSD17B7 et HSD17B12 chez des femmes atteintes d'un cancer du sein et possédant une forte histoire familiale de cancer du sein et de l'ovaire." Doctoral thesis, Université Laval, 2008. http://hdl.handle.net/20.500.11794/20495.
Books on the topic "Cancer du sein – Génétique":
T, Lynch Henry, and Kullander Stig, eds. Cancer genetics in women. Boca Raton, Fla: CRC Press, 1987.
Namer, Moïse, Michel Héry, Daniel Serin, Marc Spielmann, and Joseph Gligorov. Cancer du sein. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-71478-8.
Gros, Dominique. Cancer du sein. Paris: Springer Paris, 2009. http://dx.doi.org/10.1007/978-2-287-79503-9.
Namer, Moïse, Michel Héry, Daniel Serin, and Marc Spielmann. Cancer du sein. Paris: Springer Paris, 2006. http://dx.doi.org/10.1007/2-287-31109-2.
Namer, Moïse, Michel Héry, Marc Spielmann, Joseph Gligorov, and Frédérique Penault-Llorca. Cancer du sein. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9.
Dixon, J. M. Cancer du sein. Montréal, Québec: Modus vivendi, 2014.
Hirshaut, Yashar. Cancer du sein. Paris: Marabout, 2004.
International Conference on Carcinogenesis and Risk Assessment (9th 1995 Austin, Tex.). Etiology of breast and gynecological cancers: Proceedings of the Ninth International Conference on Carcinogenesis and Risk Assessment, held in Austin, Texas, November 29-December 2, 1995. Edited by Aldaz C. Marcelo 1956-. New York: Wiley-Liss, 1997.
es, Socie te franc ʹaise de se nologie et de pathologie mammaire Journe. Cancer du sein avance. Paris: Springer, 2007.
Serin, Daniel, and Gaëtan de Rauglaudre. Cancer du sein avancé. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-72615-6.
Book chapters on the topic "Cancer du sein – Génétique":
Sauvage, M., B. Trétarre, P. Grosclaude, F. Molinié, A. M. Aude, A. Danzon, A. V. Guizard, and P. Arveux. "Sein." In Survie des patients atteints de cancer en France, 225–32. Paris: Springer Paris, 2007. http://dx.doi.org/10.1007/978-2-287-39310-5_30.
Jaffré, I., V. Bordes, M. Dejode, F. Dravet, and J. M. Classe. "État de l’art des recommandations actuelles sur les marges de sécurité nécessaires lors de l’exérèse conservatrice d’un cancer du sein." In Cancer du sein, 1–13. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_1.
Alran, S. "Quelle place pour le ganglion sentinelle après chimiothérapie néo-adjuvante? Place d’un score clinico-biologique d’aide à la décision de ganglion sentinelle après chimiothérapie néo-adjuvante chez les patientes ayant un cancer du sein." In Cancer du sein, 127–33. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_10.
Barreau, B., F. Ettore, S. Giard, J. M. Hannoun-Levi, K. Kerrou, and O. Tredan. "Prise en charge de la récidive homolatérale d’un cancer du sein après traitement conservateur initial." In Cancer du sein, 135–64. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_11.
Bouée, S., and F. Fagnani. "Projection de l’épidémiologie du cancer du sein en 2018 en France." In Cancer du sein, 165–81. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_12.
Espié, M., A. S. Hamy, and S. Frank. "Contraception orale, traitement hormonal de la ménopause, inducteurs de l’ovulation et risque de cancer du sein." In Cancer du sein, 183–90. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_13.
Zelek, L., and T. Bouillet. "Mode de vie et cancer du sein: Les facteurs de risque non hormonaux." In Cancer du sein, 191–95. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_14.
Ancelle-Park, R. "Le dépistage organisé des cancers du sein, 20 ans après: Bénéfices et controverses." In Cancer du sein, 197–202. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_15.
Hazebroucq, V. "Le cancer du sein en France: Problèmes médicaux légaux et responsabilités." In Cancer du sein, 203–15. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_16.
Khelifa, A. "L’observatoire de la sénologie (Senolog)." In Cancer du sein, 217. Paris: Springer Paris, 2012. http://dx.doi.org/10.1007/978-2-8178-0245-9_17.
Conference papers on the topic "Cancer du sein – Génétique":
Fongaufier, C., S. Zahouily, CI Gros, S. Guihard, F. Hubelé, P. Barthélémy, and F. Bornert. "Métastases mandibulaires du cancer du sein, aspects diagnostiques et thérapeutiques : réflexion autour de 3 cas." In 65ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2017. http://dx.doi.org/10.1051/sfco/20176502024.
Richard, Amélie, Karen Reilly, and Sophie Jacquin-Courtois. "Que révèlent les disfluences sur le manque du mot rapporté par les patientes ayant un cancer du sein." In XXXIVe Journées d'Études sur la Parole -- JEP 2022. ISCA: ISCA, 2022. http://dx.doi.org/10.21437/jep.2022-38.
Reports on the topic "Cancer du sein – Génétique":
Corkum, Eleanor, Tiffanie Perrault, and Erin C. Strumpf. Améliorer les parcours de diagnostic du cancer du sein au Québec. CIRANO, October 2023. http://dx.doi.org/10.54932/tlak9928.